Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014, Article ID 703828, 5 pages
http://dx.doi.org/10.1155/2014/703828
Case Report

Myasthenia Gravis-Like Syndrome Presenting as a Component of the Paraneoplastic Syndrome of Lung Adenocarcinoma in a Nonsmoker

1Department of Internal Medicine, Jersey City Medical Center, Jersey City, NJ 07302, USA
2Department of Pulmonary and Critical Care, Jersey City Medical Center, Jersey City, NJ 07302, USA
3Department of Hematology and Oncology, Jersey City Medical Center, Jersey City, NJ 07302, USA
4Laureate National Institute of Medicine, Program Director Internal Medicine, Jersey City Medical Center, Jersey City, NJ 07302, USA

Received 3 April 2014; Revised 14 July 2014; Accepted 15 July 2014; Published 23 July 2014

Academic Editor: Francesco A. Mauri

Copyright © 2014 Sahar Eivaz-Mohammadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. S. Beckett, “Epidemiology and etiology of lung cancer,” Clinics in Chest Medicine, vol. 14, no. 1, pp. 1–16, 1993. View at Google Scholar · View at Scopus
  2. S. Dubey and C. A. Powell, “Update in lung cancer 2008,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 10, pp. 860–868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, and A. A. Adjei, “Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship,” Mayo Clinic Proceedings, vol. 83, no. 5, pp. 584–594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Heinemann, P. Zabel, and H. P. Hauber, “Paraneoplastic syndromes in lung cancer,” Cancer Therapy, vol. 6, pp. 687–698, 2008. View at Google Scholar
  5. A. M. Patel, D. G. Davila, and S. G. Peters, “Paraneoplastic syndromes associated with lung cancer,” Mayo Clinic Proceedings, vol. 68, no. 3, pp. 278–287, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. B. M. Conti-Fine, M. Milani, and H. J. Kaminski, “Myasthenia gravis: past, present, and future,” Journal of Clinical Investigation, vol. 116, no. 11, pp. 2843–2854, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. Peltier, B. K. Black, S. R. Raj, P. Donofrio, D. Robertson, and I. Biaggioni, “Coexistent autoimmune autonomic ganglionopathy and myasthenia gravis associated with non-small-cell lung cancer,” Muscle and Nerve, vol. 41, no. 3, pp. 416–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Kirchner, S. Tzartos, F. Hoppe, B. Schalke, H. Wekerle, and H. K. Muller-Hermelink, “Pathogenesis of myasthenia gravis: acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors,” American Journal of Pathology, vol. 130, no. 2, pp. 268–280, 1988. View at Google Scholar · View at Scopus
  9. S. Vernino, J. Lindstrom, S. Hopkins, Z. Wang, and P. A. Low, “Characterization of ganglionic acetylcholine receptor autoantibodies,” Journal of Neuroimmunology, vol. 197, no. 1, pp. 63–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Chini, F. Clementi, N. Hukovic, and E. Sher, “Neuronal-type α-bungarotoxin receptors and the α5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 5, pp. 1572–1576, 1992. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Mihovilovic, C. Hulette, J. Mittelstaedt, C. Austin, and A. D. Roses, “Nicotinic neuronal acetylcholine receptor α-3 subunit transcription in normal and Myasthenic thymus,” Annals of the New York Academy of Sciences, vol. 681, pp. 83–96, 1993. View at Google Scholar · View at Scopus
  12. M. Mihovilovic and J. Butterworth-Robinette, “Thymic epithelial cell line expresses transcripts encoding α-3, α-5 and β-4 subunits of acetylcholine receptors, responds to cholinergic agents and expresses choline acetyl transferase. An in vitro system to investigate thymic cholinergic mechanisms,” Journal of Neuroimmunology, vol. 117, no. 1-2, pp. 58–67, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. N. P. Hirsch, “Neuromuscular junction in health and disease,” British Journal of Anaesthesia, vol. 99, no. 1, pp. 132–138, 2007. View at Publisher · View at Google Scholar
  14. M. Abel and J. B. Eisenkraft, “Anesthetic implications of myasthenia gravis,” Mount Sinai Journal of Medicine, vol. 69, no. 1-2, pp. 31–37, 2002. View at Google Scholar · View at Scopus
  15. L. C. Pelosof and D. E. Gerber, “Paraneoplastic syndromes: an approach to diagnosis and treatment,” Mayo Clinic Proceedings, vol. 85, no. 9, pp. 838–854, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Yu and V. A. Lennon, “Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases,” Th New England Journal of Medicine, vol. 340, no. 3, pp. 227–228, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Keime-Guibert, F. Graus, A. Fleury et al., “Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone,” Journal of Neurology Neurosurgery and Psychiatry, vol. 68, no. 4, pp. 479–482, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Uchuya, F. Graus, F. Vega, R. René, and J.-Y. Delattre, “Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies,” Journal of Neurology Neurosurgery and Psychiatry, vol. 60, no. 4, pp. 388–392, 1996. View at Publisher · View at Google Scholar · View at Scopus